LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06479759 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

NSCLC
PD-1

Interventions

DRUG: LM-108 antibody and sintilimab
DRUG: LM-108 antibody and sintilimab and chemotherapy

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China